Comprehensive treatment of Eales’ disease by Borowicz, Dorota et al.
151Copyright © 2016 Via Medica, ISSN 2450–7873
CASE REPORT
DOI: 10.5603/OJ.2016.0028
Corresponding author: 
Dorota Borowicz, Department of General Ophthalmology, Medical University in Lublin, Chmielna 1 St., 20–079 Lublin, Poland, e-mail: dorotajjj2@wp.pl
Comprehensive treatment of Eales’ disease
dorota Borowicz, edyta Koman, Katarzyna nowomiejska, robert rejdak 
Department of General Ophthalmology, Medical University in Lublin, Lublin, Poland
aBstraCt
Eales’ disease (ED) is an idiopathic, obliterative vasculopathy typically affecting the peripheral retina among healthy 
young adults. ED is characterised by retinal vasculitis, occlusion, and neovascularisation. The aetiology of the ED is 
unknown, but in recent years immunological, biological studies have suggested the role of human leukocyte antigen, 
retinal autoimmunity, and mycobacterium tuberculosis genome in the aetiology of this disease. The medical treat-
ment consists of use of oral corticosteroids, laser photocoagulation, anti-VEGF injections, corticosteroid injections, 
or vitreoretinal surgery. This article describes all these modes of treatment in a young patient suffering from Eales’ 
disease.
KeY Words:  Eales’ disease, retinal vasculitis, photocoagulation, vitreoretinal surgery
Ophthalmol J 2016; Vol. 1, No. 4, 151–155
introduCtion
Eales’ disease is an idiopathic, obliterative vas-
culopathy typically affecting the peripheral retina 
among healthy young male adults, in the second 
through fourth decades of life. This disease is ob-
served more often in the Indian subcontinent than 
in the rest of the world. The aetiology of this disease 
is unknown, but in recent years immunological, 
biological studies have suggested the role of human 
leukocyte antigen, retinal autoimmunity, and my-
cobacterium tuberculosis genome in the aetiology 
of this disease. The first case of Eales’ disease was 
described in 1880 by Henry Eales, a British oph-
thalmologist. The retinal changes include vasculitis, 
extensive peripheral non-perfusion, and neovascu-
larisation. Neovascularisation of the retina occurs 
in up to 80% of the patients. The new vessels are 
formed on the disc (NVD) or on the retina (NVE). 
Bleeding from neovascularisation is one of the ma-
jor causes of vision loss. Sometimes epiretinal mem-
brane and macular oedema are presented. The clin-
ical picture is similar to other diseases of the retina, 
such as diabetic retinopathy, sarcoidosis, collagen 
diseases, haemoglobinopathy, leukaemia, Behcet’s 
disease, toxoplasmosis, tuberculosis, and Wegener’s 
granulomatosis. The management depends on the 
stage of the disease and consists of medical treat-
ment with oral corticosteroids, antituberculous 
therapy in the active inflammatory stage, and laser 
photocoagulation and anti-VEGF in the advanced 
retinal ischaemia and neovascularisation stages. In 
macular oedema corticosteroid/triamcinolone ace-
tonide injections are given [1–3].
The results of vitreoretinal surgery have been 
found to be satisfactory in cases of vitreous haemor-
rhage with or without retinal detachment. 
This article describes the case of a patient with 
Eales’ disease. 
Case report
The 20-year-old man reported to the De-
partment of Ophthalmology in Lublin in March 
2011 complaining about gradually progressive, 
painless diminution of vision and widened pupil in 
the right eye for more  than week. His visual acuity 
was 0.6 in the right eye and 1.0 in the left, and the 
intraocular pressure was 35 mm Hg in the right eye 
and 22 mm Hg in the left eye. Ophthalmologic 
examination showed: iris rubeosis, widened pupil, 
vitreous floaters, veins periodically narrowed, and 
single haemorrhage at the fundus in the right eye 
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Figure 1. Fundus photography of both eyes (right on the right side, left on the left side)
and veins periodically narrowed in left eye. These 
changes suggested retinal ischaemia. Based on a fun-
dus examination of the right eye, Eales’ disease was 
diagnosed (Fig. 1). The patient was qualified to 
the injection of Avastin on the right eye and laser 
photocoagulation in both eyes. He was given two 
antiglaucomatous drugs (combined timolol/isocar-
bamid and brimonidine). The patient had macu-
lar oedema in both eyes on OCT in August 2011 
(Figs. 2 and 3). Once again he was qualified to be 
Figure 2. Macular oedema in optical coherence tomography of the right eye in 2011
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Figure 3. Macular oedema in optical coherence tomography of the left eye in 2011
given intravitreal injection of bevacizumab to both 
eyes. In the right eye the swelling decreased, while 
the swelling grew in the left eye. The ranibizumab 
injection was given to the left eye. Vitreous haemor-
rhage was reported in the right eye, and the patient 
was qualified for vitreoretinal surgery in November 
2012. Vitrectomy surgery with gas tamponade was 
performed on right eye in the same month. Visual 
acuity at the control visit was 0.7 cc –1.0 in the 
right eye and 0.2 in the left eye, and the intraocular 
pressure was normal. Macular oedema grew up on 
the left eye, so the patient was qualified to triam-
cinolone acetonide injection. During examination 
a cataract was noticed in both eyes. The patient was 
qualified for surgery of the cataracts (the left eye in 
2014; the right eye in 2016). ERM was seen over 
the surface of the retina in the left eye in 2015. 
Vitrectomy surgery containing peeling ILM was 
performed in the left eye in August 2015. The pa-
tient’s visual acuity was 0.8 in the right eye and 
0.1 in the left eye in September 2016 (Figs. 4 and 5).
disCussion
ED is an idiopathic inflammatory venous oc-
clusion that primarily affects the peripheral retina. 
This disease is characteristic for healthy young men 
(20–40 years old) and rarely appears in developed 
countries. 
Oxidative stress is considered as a major factor 
contributing to the pathogenesis of ED. Patients 
with ED have vitreous containing high levels of 
angiogenic growth factors, VEGF, IL-6 and IL-8, 
and MCP-1 [2].
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Stages of ED include retinal phlebitis, peripheral 
non-perfusion, and retinal neovascularisation. The 
new staging system for Eales’ disease is [2]:
•	 I Periphlebitis of small (Ia) and large (Ib) calibre 
vessels with superficial retinal haemorrhages;
•	 IIa Capillary non-perfusion;
•	 IIb Revascularisation elsewhere/of the disc;
•	 IIIa Fibrovascular proliferation;
•	 IIIb Vitreous haemorrhage;
•	 IVa Traction/combined rhegmatogenous reti-
nal detachment;
•	 IVb Rubeosis iridis, neovascular glaucoma, com-
plicated cataract, and optic atrophy.
Most patients present symptoms of floaters, 
specks, cobwebs, blurring, or decreased vision as-
sociated with vitreous haemorrhage. Bilateral in-
volvement is evident in 80–90% of patients. The 
major manifestations of ED are inflammation, ne-
ovascularisation, vitreous haemorrhage, and retinal 
detachment. Macular involvement (macular oede-
ma and ERM formation) in Eales’ disease has been 
described [1, 4–6]. 
The management depends on the stage of the 
disease and consists of medical treatment with oral 
corticosteroids, antituberculous therapy in the ac-
tive inflammatory stage, and laser photocoagulation 
and anti-VEGF in the advanced retinal ischaemia 
and neovascularisation stages. In macular oedema 
corticosteroid/triamcinolone acetonide injections are 
given. The results of vitreoretinal surgery have been 
Figure 4. Macular oedema in optical coherence tomography of the right eye in 2016
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found to be satisfactory in cases of vitreous haemor-
rhage with or without retinal detachment [1, 4–6].
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Figure 5. Macular oedema in optical coherence tomography of the left eye in 2016

